These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7110143)

  • 21. Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives.
    Jain V; Vyas SP; Kohli DV
    Nanomedicine; 2009 Sep; 5(3):334-44. PubMed ID: 19523433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
    Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of thymus for N-acetyl muramyl-L-alanyl-D-isoglutamine-induced polyarthritis and granuloma formation in euthymic and athymic nude rats or in neonatally thymectomized rats.
    Kohashi O; Pearson CM; Tamaoki N; Tanaka A; Shimamura K; Ozawa A; Kotani S; Saito M; Hioki K
    Infect Immun; 1981 Feb; 31(2):758-66. PubMed ID: 7012019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Preparation and characteristics of monoclonal antibodies to N-acetylglucosaminyl-(beta1-4)-N-acetylmuramoyl-alanyl-D-isoglutamine].
    Mareeva TIu; Kotova OV; Makarov EA; Andronova TM; Nesmeianov VA
    Bioorg Khim; 1993 May; 19(5):555-61. PubMed ID: 8318024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marked enhancement in vivo of adjuvant activity of muramyl dipeptide to protein antigens and to synthetic weak immunogens with monoclonal anti-muramyl dipeptide antibodies.
    Bahr GM; Tello DS; Chedid LA
    Infect Immun; 1985 Aug; 49(2):312-9. PubMed ID: 4018873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
    Durette PL; Dorn CP; Friedman A; Schlabach A
    J Med Chem; 1982 Sep; 25(9):1028-33. PubMed ID: 7131480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.
    Kosugi A; Shima J; Sano H; Ogata M; Kusama T; Fujiwara H; Hamaoka T
    Infect Immun; 1986 Dec; 54(3):768-73. PubMed ID: 3491048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereo-isomer specific induction of renal cell apoptosis by synthetic muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-isoglutamine).
    Langford MP; Chen D; Welbourne TC; Redens TB; Ganley JP
    Mol Cell Biochem; 2002 Jul; 236(1-2):63-73. PubMed ID: 12190122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo effects of ovalbumin-conjugated muramyl peptides on the anti-ovalbumin IgE and IgG responses in mice.
    Prouvost-Danon A; Bahr GM; Chedid L; Ekwalanga M; Bassot S
    Int J Immunopharmacol; 1984; 6(5):425-31. PubMed ID: 6500780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of fluorescent muramyl dipeptide congeners. 2.
    Hiebert CK; Kopp WC; Richerson HB; Barfknecht CF
    J Med Chem; 1988 Oct; 31(10):2022-4. PubMed ID: 3172138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant activity of carbohydrate analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine on the induction of delayed-type hypersensitivity to azobenzenearsonate-N-acetyl-L-tyrosine in guinea pigs.
    Azuma I; Okumura H; Saiki I; Kiso M; Hasegawa A; Tanio Y; Yamamura Y
    Infect Immun; 1981 Sep; 33(3):834-9. PubMed ID: 7287186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier.
    Chedid L; Parant M; Parant F; Audibert F; Lefrancier F; Choay J; Sela M
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6557-61. PubMed ID: 293743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Augmentation of the proliferative response of thymocytes to phytohemagglutinin by the muramyl dipeptide1.
    Iribe H; Koga T
    Cell Immunol; 1984 Oct; 88(1):9-15. PubMed ID: 6332683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opposite effects of the synthetic adjuvant N-acetyl-muramyl-L-alanyl-D-isoglutamine on the immune response in mice depending on experimental conditions.
    Souvannavong V; Adam A
    Eur J Immunol; 1980 Aug; 10(8):654-6. PubMed ID: 6995138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of a high affinity antibody specific to the calcium-free-form of calmodulin, using N-acetyl-muramyl-L-alanyl-D-isoglutamine-calmodulin conjugate.
    Slaninová J; Thorn NA
    J Immunoassay; 1983; 4(4):395-406. PubMed ID: 6668360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP.
    Leclerc C; Juy D; Bourgeois E; Chedid L
    Cell Immunol; 1979 Jun; 45(1):199-206. PubMed ID: 313275
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunostimulatory activity of 1-O-acylated muramyl dipeptides, with or without a 6-O-phosphoryl group, in aqueous form.
    Furuya T; Kumazawa Y; Takimoto H; Nagumo T; Nagamine T; Aizawa C; Mizunoe K; Kiso M; Hasegawa A; Nomoto K
    Int J Immunopharmacol; 1989; 11(1):35-43. PubMed ID: 2496044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
    Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
    Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.